Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1163999.RAL0-J5HBhr4hk6Tg2gutI6xBNg1Z1vkxqmqadrBchVfw130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1163999.RAL0-J5HBhr4hk6Tg2gutI6xBNg1Z1vkxqmqadrBchVfw130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1163999.RAL0-J5HBhr4hk6Tg2gutI6xBNg1Z1vkxqmqadrBchVfw130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1163999.RAL0-J5HBhr4hk6Tg2gutI6xBNg1Z1vkxqmqadrBchVfw130_provenance.
- NP1163999.RAL0-J5HBhr4hk6Tg2gutI6xBNg1Z1vkxqmqadrBchVfw130_assertion description "[Monitoring of minimal residual disease (MRD) by quantification of BCR-ABL1 transcript levels has become a main part of the management of patients with BCR-ABL1-positive acute lymphoblastic leukemia (ALL) in treatment with tyrosine kinase inhibitors (TKIs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1163999.RAL0-J5HBhr4hk6Tg2gutI6xBNg1Z1vkxqmqadrBchVfw130_provenance.
- NP1163999.RAL0-J5HBhr4hk6Tg2gutI6xBNg1Z1vkxqmqadrBchVfw130_assertion evidence source_evidence_literature NP1163999.RAL0-J5HBhr4hk6Tg2gutI6xBNg1Z1vkxqmqadrBchVfw130_provenance.
- NP1163999.RAL0-J5HBhr4hk6Tg2gutI6xBNg1Z1vkxqmqadrBchVfw130_assertion SIO_000772 24630366 NP1163999.RAL0-J5HBhr4hk6Tg2gutI6xBNg1Z1vkxqmqadrBchVfw130_provenance.
- NP1163999.RAL0-J5HBhr4hk6Tg2gutI6xBNg1Z1vkxqmqadrBchVfw130_assertion wasDerivedFrom befree-2016 NP1163999.RAL0-J5HBhr4hk6Tg2gutI6xBNg1Z1vkxqmqadrBchVfw130_provenance.
- NP1163999.RAL0-J5HBhr4hk6Tg2gutI6xBNg1Z1vkxqmqadrBchVfw130_assertion wasGeneratedBy ECO_0000203 NP1163999.RAL0-J5HBhr4hk6Tg2gutI6xBNg1Z1vkxqmqadrBchVfw130_provenance.
- befree-2016 importedOn "2016-02-19" NP1163999.RAL0-J5HBhr4hk6Tg2gutI6xBNg1Z1vkxqmqadrBchVfw130_provenance.